Roche buys into gene therapies with $4.8bn Spark acquisition 25-Feb-2019 By Ben Hargreaves Roche gains access to Spark’s potential gene therapy treatments for haemophilia to complement its existing portfolio in the space.
Novartis one-time gene therapy demands ‘rethink’ of healthcare costing 27-Nov-2018 By Ben Hargreaves Luxturna has been approved by Europe but the treatment may require a revaluation of cost-effectiveness evaluations, suggests Novartis UK CSO.